*

†

Address correspondence to Rojelio Mejia, Laboratory of Clinical Parasitology and Diagnostics, National School of Tropical Medicine, One Baylor Plaza, Baylor College of Medicine 113, Houston, TX 77030. E-mail: rojelio.mejia@bcm.edu

†These authors contributed equally to this work.

fn2Authors’ addresses: Megan L. McKenna, Shannon McAtee, Patricia E. Bryan, Rebecca Jeun, Tabitha Ward, Jacob Kraus, Maria E. Bottazzi, Peter J. Hotez, and Rojelio Mejia, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX, E-mails: mmckenna@bcm.edu, shannon.mcatee@gmail.com, patricia.e.bryan@uth.tmc.edu, rjeun1@jhmi.edu, tabitha.ward@bcm.edu, jcbkraus@gmail.com, bottazzi@bcm.edu, hotez@bcm.edu, and rojelio.mejia@bcm.edu. Catherine C. Flowers, Alabama Center for Rural Enterprise, Montgomery, AL, E-mail: catherineflowers@aol.com.

Financial support: Funding provided by the Texas Children’s Hospital Center for Vaccine Development, and the National School of Tropical Medicine, Baylor College of Medicine. Disclosure: R. M. has received travel support from Romark Pharmaceuticals, the makers of nitazoxanide. This study was completed before the association and was not influenced by this relationship. P. J. H. and M. E. B. are principal investigators and patent-holders on vaccines for hookworm and schistosomiasis, currently in clinical trials, as well as several other neglected tropical medicine disease vaccines currently in development. Other authors report no conflicts of interests, have participated in the study, and concur with the submission.